Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-08-18
2008-08-05
Epperson, Jon D. (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S003100, C514S021800, C530S300000
Reexamination Certificate
active
07407934
ABSTRACT:
Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are also described.
REFERENCES:
patent: 4451394 (1984-05-01), Sarantakis
patent: 5124314 (1992-06-01), Cooper
patent: 5166192 (1992-11-01), Mathias
patent: 5175145 (1992-12-01), Cooper
patent: 5187154 (1993-02-01), Phillips et al.
patent: 5234906 (1993-08-01), Young et al.
patent: 5260275 (1993-11-01), Cooper et al.
patent: 5264372 (1993-11-01), Beaumont et al.
patent: 5266561 (1993-11-01), Cooper et al.
patent: 5281581 (1994-01-01), Cooper et al.
patent: 5367052 (1994-11-01), Cooper et al.
patent: 5376638 (1994-12-01), Young et al.
patent: 5580953 (1996-12-01), Albrecht et al.
patent: 5686411 (1997-11-01), Gaeta et al.
patent: 5817634 (1998-10-01), Meezan et al.
patent: 6114304 (2000-09-01), Kolterman et al.
patent: 6136820 (2000-10-01), Liu et al.
patent: 6417164 (2002-07-01), Kolterman et al.
patent: 7271238 (2007-09-01), Gaeta et al.
patent: 0 289 287 (1988-11-01), None
patent: 92/20367 (1992-11-01), None
patent: 93/10146 (1993-05-01), None
patent: 93/10147 (1993-05-01), None
Pittner et al., Journal of Cellular Biocheistry. vol. 55S: 19-28; 1994.
Edwards et al., Life Sciences. vol. 51:1899-1912; 1992.
El-Andaloussi et al., Current Pharmaceutical Design. vol. 11: 3597-3611; 2005.
Alam et al., “Selective Antagonism of Calcitonin-induced Osteoclastic Quiescence (Q Effect) by Human Calcitonin Gene-Related Peptide-(Val8Phe37)”,BIochem. Biophys. Res. Commun., 179(1):134-139 (1991).
Amara et al., “Expression in Brain of a Messenger RNA Encoding a Novel Neuropeptide Homologous to Calcitonin Gene-Related Peptide”,Science, 229:1094-1097 (1985).
Brain et al., “Amylin Amide, Which is Structurally Similar to Calcitonin Gene-Related Peptide (CGRP), Stimulates Increased Blood Flow In Vivo”,Eur. J. Pharmacol., 183:221 (1990).
Brener et al., “Regulation of the Gastric Emptying of Glucose”,Gatroenterology, 85:76-82 (1983).
Briner et al., “Tageszeitliche Schwangkungen der Glukose-toleranz bei Diabetikern und Nichtdiabetiker, unter besonderer Berücksichtgung der Magenentleerung”,Schweiz Rundsh Med, Prax., 68:1666-1672 (1979).
Broderick et al., “Human and Rat Amylin have no Effects on Insulin Secretion in Isolated Rat Pancreatic Islets”,Biochem. Biophys. Res. Comm., 177:932-938 (1991).
Camilleri & Malagelada, “Abnormal Intestinal Motility in Diabetes with the Gastroparesis Syndrome”,European Journal of Clinical Investigation, 14:420-427 (1984).
Campbell et al., “Gastric Emptying in Diabetic Autonomic Neuropathy”,Gut,18:462-467 (1977).
Cavallo-Perin et al., “Gastric Emptying of Liquids and Solids Evaluated by Acetaminophen Test in Diabetic Patients with and without Autonomic Neuropathy”,European Review of Medical&Pharmacological Sciences, XIII:205-209 (1991).
Chance et al., “Anorexia Following the Intrahypothalamic Administration of Amylin”,Brain Research, 539:352-354 (1991).
Chantry et al., “Cross-reactivity of Amylin with Calcitonin-Gene-Related Peptide Binding Sites in Rat Liver and Skeletal Muscle Membranes”,Biochem. J., 277:139-143 (1991).
Clouse and Lustman, “Gastrointestinal Symptoms in Diabetic Patients: Lack of Association with Neuropathy”,The American Journal of Gastroenterology, 84(8):868-872 (1989).
Cohen et al.,The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation (1989).
Cooper et al., “Purification and Characterization of a Peptide from Amyloid-Rich Pancreases of Type 2 Diabetic Patients”,Proc. Natl. Acad. Sci. USA, 84:8628-8632 (1987).
Cooper et al., “Amyline Found in Amyloid Deposits in Human Type 2 Diabetes Mellitus May be a Hormone that Regulates Glycogen Metabolism Skeletal Muscle”,Proc. Natl. Acad. Sci. USA, 85:7763-7766 (1988).
Cooper et al., “The Amylin Superfamily: A Novel Grouping of Biologically Active Polypeptides Related to the Insulin A-Chain”,Progress in Growth Factor Research, 1:99-105 (1989).
Cooper et al., “Amylin and the Amylin Gene: Structure, Function and Relationship to Islet Amyloid and to Diabetes Mellitus”,Biochem. Biophysica Acta., 1014:247-258 (1989).
Cooper et al., “Amylin Action: Physiologic Basis and Pathologic Correlations”,Diabetes, 497-500 (1991).
Cotroneo et al., “Gastric Emptying Rate and Hormonal Response in Type II Diabetics”,Diabetes Res., 17:99-104 (1991).
Daniel et al., “Use of Glucagon in the Treatment of Acute Diverticulitis”,Br. Med. J., 3:720 (1974).
Dao et al., “Lack of Modulation of Gastric Emptying by Acute Hyperglycemia in Tpye 2 Diabetes Mellitus”,Gastroenterology, 98:A342 (1990).
Deems et al., “Amylin or CGRP (-37) Fragments Reverse Amylin-Induced Inhibition of14C-Glycogen Accumulation”,Biochem. Biophys. Res. Comm., 181(1):116-120 (1991).
Eisenberg et al., “Synchronous Gastric Motor and Secretory Activity in Normal and Diabetic Dogs: The importance of Variation in Blood Sugar Levels”,Bulletin de la Societe Internationale de Chirurgie, 3:191-198 (1972).
Feldman et al., “Abnormal Gastric Function in Longstanding, Insulin-Dependent Diabetic Patients”,Gastroenterology, 77:12-17 (1979).
Feldman et al., “Disorders of Gastrointestinal Motility Associated with Diabetes Mellitus”,Ann. Int. Med., 98:378-384 (1983).
Feldman et al., “Gastric Emptying of Solid Radiopaque Markers: Studies in Healthy Subjects and Diabetic Patients”,Gastroenterology, 87:895-902 (1984).
Follett et al., “Effect of Amylin on Insulin Receptor Kinase Activity In Vivo in the Rat”,Clinical Research, 39(1):39A (1991).
Forster and Dockray, “Immunoneutralization suggests that calcitonin gene related peptide regulates gastric emptying in the rat”,Neurosci. Lett., 131:5-7 (1991).
Franken et al., “The Use of Glucagon in Hydrostatic Reduction of Intussusception: A Double-Blind Study of 30 Patients”,Radiology, 146:687 (1983).
Fraser et al., “Hyperglycaemia slows gastric emptying in Type I (insulin-dependent) diabetes mellitus”,Diabetologia, 33:675-680 (1990).
Fraser et al., “Hyperglycaemia Stimulates Pyloric Motility in Normal Subjects”,Gut, 32:475-478 (1991).
Fraser et al., “Effect of Insulin-Induced Hypoglycaemia in Antral, Pyloric and Duodenal Motility in Fasting Subjects”,Clin. Sci., 81:281-285 (1991).
Frontoni et al., “In Vivo Insulin Resistance Induced by Amylin Primarily Through Inhibition of Insulin-Stimulated Glycogen Synthesis in Skeletal Muscle”,Diabetes, 40:568-573 (1991).
Gaber et al., “Changes in Gastric Emptying in Recipients of Successful Combined Pancreas-Kidney Transplants”,Dig. Dis., 9:437-443 (1991).
Galeazza et al., “Islet Amyloid Polypeptide (IAPP) Competes for Two Binding Sites of CGRP”,Peptides, 12:585-591 (1991).
Gardiner et al., “Antagonistic Effect of Human α-Calcitonin Gene-related Peptide (8-37) on regional Hemodynamic Actions of Rat Islet Amyloid Polypeptide in Conscious Long-Evans Rats”,Diabetes, 40:948-951 (1991).
Gedulin et al., “Amylin Secretion from the Perfused Pancreas: Dissociation from Insulin and Abnormal Elevation in Insulin-Resistant Diabetic Rats”,Biochem. Biophys. Res. Commun., 180(2);782-789 (1991).
Gilbey et al., “Amylin Lowers Serum Calcium in Pagets Bond Disease Further Evidence for a Role in Calcium Metabolism”,J. Bone Mineral Res., S293 (1991).
Gill et al., “Effects of Ciglitazone on Endogenous Plasma Islet Amyloid Polypeptides and Insulin Sensitivity in Obese-Di
Brown Kathleen Ann Keating
Kolterman Orville G.
Rink Timothy J.
Young Andrew A.
Amylin Pharmaceuticals Inc.
Epperson Jon D.
Intellectual Property Group Amylin Pharmaceuticals, Inc.
Liu Sue
LandOfFree
Methods for regulating postprandial blood glucose does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for regulating postprandial blood glucose, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for regulating postprandial blood glucose will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3994183